Full Year 2018 Futura Medical PLC Earnings Call Transcript
Okay, well, first of all, I'd like to thank you all for joining Futura's prelim webcast this morning, analyst meeting, and also thank those that are listening to the webcast. I'm joined today by Ken James, who's Executive Head of R&D; and also by Angela Hildreth, who's the Finance Director and Chief Operating Officer of Futura.
If you want to turn to Slide 5. And it showed a corporate overview about Futura. We're obviously listed on AIM, and we describe ourselves as a virtual organization with 15 staff and a low overhead base. We have a significant outsourced infrastructure with over 30 consultants. Dermasys is our key sort of asset. It's our transdermal delivery system, which enables existing pharmaceutical drugs for improved or new indications. We don't, at this stage, look at new clinical indications so it does derisk the process. We've got an excellent safety profile -- the Dermasys system has an excellent safety profile with no harsh permeation enhancers.
Our track record is we're very good at clinically
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
